Volume 5, Number 3—June 1999
Hepatitis C Virus RNA Viremia in Central Africa
To the Editor: Epidemiologic serosurveys have demonstrated high prevalence (6%-15%) of hepatitis C virus (HCV) infection in adults in sub-Saharan Africa (1-4). Although possible false-positive HCV serologic test results have been reported in Africa, HCV prevalence rates suggest a high rate of chronic infection among persons with anti-HCV antibodies (5,6). We have focused on HCV RNA infectivity of blood from donors attending the National Blood Center in Bangui, Central African Republic.
We prospectively tested all blood donors between February and April 1998 for serum anti-HCV antibodies by both an HCV third-generation enzyme-linked immunosorbent assay (ELISA) (Abbott HCV EIA 3.0 test, Abbott, Chicago, IL, USA), which was chosen as a reference test for immunoglobulin (Ig) G antibodies to HCV, and by a simple membrane immunoassay system (Ortho HCV Ab Quik Pack, Ortho Diagnostic Systems Inc., Tokyo, Japan) (7). Anti-HCV-positive serum samples were further subjected to qualitative detection of HCV RNA by reverse transcription-polymerase chain reaction (AMPLICOR-HCV, Roche Diagnostic Systems, Inc., Branchburg, NJ, USA) (8). Of 163 serum samples (mean age ± standard deviation, 30±8 years), 155 were from male blood donors, 83 (51%) from first-time donors, and 125 (77%) from donors in the recipient's family. Fifteen (9.2%; 95% confidence interval [CI] 5%-15%) samples contained IgG to HCV by ELISA. Of the ELISA-positive samples, 14 were positive by the Quik Pack assay (sensitivity, 93.0%); of the 148 remaining ELISA-negative samples, 147 were negative by the Quik Pack assay (specificity, 99.3%). The agreement between the results of the two methods was 98.7%. Of the 163 samples, 10 (6.1%; CI 95%: 3%-11%) were positive for HCV antibodies (by ELISA and rapid test) and for HCV RNA.
We confirmed a high prevalence of HCV-seropositivity among blood donors in Bangui and the subsequent high rate of HCV RNA viremic blood donations. To offset the major risk for transfusion-acquired HCV in Central Africa we recommend screening donated blood for anti-HCV. When laboratory facilities to perform ELISA are not available, the Quik Pack system, a simple reliable method for detecting anti-HCV antibodies in human serum that requires neither complex reagent preparation nor expensive instrumentation, could prove useful.
- Ndumbe PM, Skalsky J. Hepatitis C virus infection in different populations in Cameroon. Scand J Infect Dis. 1993;25:689–92.
- Xu LZ, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 highly prevalent in Central Africa (Gabon). J Gen Virol. 1994;75:2393–8.
- Fretz C, Jeannel D, Stuyver L, Herve V, Lunel F, Boudifa A, HCV Infection in a rural population of Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol. 1995;47:435–7.
- Pawlotsky JM, Bélec L, Grésenguet G, Desforges L, Bouvier M, Duval J, High prevalence of hepatitis B, C and E markers in young sexually active adults from the Central African Republic. J Med Virol. 1995;46:269–73.
- Aceti A, Taliani D. Hepatitis C virus testing in African sera. Ann Intern Med. 1992;116:427.
- Callahan JD, Constantine NT, Kataaha P, Zhang X, Hyams KC, Bansal J. Second generation hepatitis C virus assays: performance when testing African sera. J Med Virol. 1993;41:35–8.
- Kodama T, Ichiyama S, Sato K, Nada T, Nakashima N. Evaluation of a membrane filter assay system, Ortho HCV Ab Quik Pack, for detection of anti-hepatitis C virus antibody. J Clin Microbiol. 1998;36:1439–40.
- Young KKY. R. Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993;31:882–6.
Suggested citation: Cancré N, Grésenguet G, Mbopi-Kéou F-X, Kozemaka A, Mohamed AS, Matta M, et al. Hepatitis C Virus RNA Viremia in Central Africa [letter]. Emerg Infect Dis [serial on the Internet]. 1999, Jun [date cited]. Available from http://wwwnc.cdc.gov/eid/article/5/3/99-0330 Cancré
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 13, 2010
- Page last updated: December 13, 2010
- Page last reviewed: December 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)